Omadacycline therapy for Mycobacterium abscessus species infections.

Paul Robert IngramEva E JonesBethwyn AllenRonan J MurrayTerillee J KeehnerTimothy J Whitmore

Published in: Internal medicine journal (2023)

Although this limited observational data and in-vitro susceptibility results are encouraging, randomised control trials are required to determine the role of omadacycline as part of combination therapy for this most difficult to treat pathogen. This article is protected by copyright. All rights reserved.

Keyphrases

clinical trial
open label
mycobacterium tuberculosis
electronic health record
double blind
study protocol
big data
candida albicans
placebo controlled
cross sectional
genetic diversity